Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

rate ("CER") basis, which is a Non GAAP measure, product sales were up 25%.

Product sales in the quarter benefited from higher ADDERALL XR® sales, in part due to significantly lower sales deductions following a lowering of the estimate of inventory in the US retail pipeline.

  • The strong product sales growth more than offset declines in 3TC® and ZEFFIX® royalties, both of which are now affected by the disagreement with GlaxoSmithKline ("GSK"), to give growth in total revenues of 24%, to $1,086 million in the quarter (Q3 2010: $874 million).


 

  • As expected, research and development ("R&D") was up 21% on a Non GAAP basis compared to Q3 2010, as we continue to invest in both early and late stage programs across our business to enable us to deliver future growth. On a US GAAP basis, R&D expenditure increased 2% compared to Q3 2010.


 

  • Non GAAP operating income was up 15% to $341 million (Q3 2010: $298 million). As expected, Non GAAP operating expenses increased at broadly the same rate as the increase in product sales compared to Q3 2010. This increase was due to increased investment in our R&D program and higher selling, general and administrative ("SG&A") expenditure as we absorb the operating costs of Advanced BioHealing Inc. ("ABH") and Movetis, neither of which were incurred in Q3 2010, in addition to supporting product launches and our continued growth.


 

Non GAAP diluted earnings per American Depositary Share ("ADS") were up 10% to $1.28 (Q3 2010: $1.16), due to the higher Non GAAP operating income, partially offset by higher Non GAAP Other Expenses.

  • On a US GAAP basis, operating income was up 64% to $255 million (Q3 2010: $156 million). Q3
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized and ... 29-30 in San Francisco, CA. This year’s conference brings ... and clinicians focused on addressing and solving the significant ... twelve years since the sequencing of the human genome, ... pharmacogenetic information in the label and molecular diagnostics have ...
(Date:8/20/2014)... 2014 WriteResult®, a leading provider of ... has expanded its myPROpad™ ePRO tablet with the addition ... of the most widely used and well-respected Patient Reported ... The EQ-5D is used during clinical trials and in ... can be used to demonstrate Health-Related Quality of Life ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets  has ... - Global Strategic Business Report" report to their offering. ... Tissue Culture Supplies in US$ Thousands by the following Product Segments: ... analytics for the US, Canada , ... , and Latin America . Annual estimates ...
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... In a visit to the Menomonee Valley, Gov. Jim ... his 2007-09 state budget for the new Wisconsin Venture Center. ... sector partnership that will connect entrepreneurs with sources of capital, ... seeking deals in Wisconsin. , ,The concept was announced in ...
... - Wisconsin officials and investors who are trying to ... life science firm to relocate here have a fight on ... willing to let go of Aruna Biomedical , an ... researchers and is seeking to move from research to production. ...
... Strong, who has served as vice president of ... appointed president and chief operating officer of the Madison-based ... the company's board of directors and announced at the ... chemistry degree from the University of Wisconsin-Madison , ...
Cached Biology Technology:Doyle proposes $2M for venture capital center 2Wisconsin won't get Georgia biotech without a fight 2Wisconsin won't get Georgia biotech without a fight 3
(Date:8/20/2014)... by researchers at the University of Missouri School of ... life-threatening heart condition caused by muscular dystrophy. , ... Ph.D., the leading author of the study and assistant ... of Molecular Microbiology and Immunology. "This is just a ... a treatment for people with this devastating heart condition, ...
(Date:8/20/2014)... absorbs light and its energy is finally utilized ... Photovoltaic devices, mostly build from silicon based semiconductors, ... approach for the development of cheaper and renewable ... isolated membrane protein complexes of photosynthesis. Prof. Dr. ... from thermophilic cyanobacteria that live in a hot ...
(Date:8/19/2014)... China,s increasing caesarean section rate, suggests a new commentary ... Journal of Obstetrics and Gynaecology (BJOG) . , China ... the world. Of 16 million babies born in 2010, ... is not known, the current Chinese language literature on ... from 36% to 58%. However, before the 1980s, the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2A semi-artificial leaf faster than 'natural' photosynthesis 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... traditional practice in animal testing has been standardization, but ... as few as two controlled environmental variables to preclinical ... number of animals needed for testing and the cost ... assistant professor of animal sciences, said the finding challenges ...
... field of golden-flowered stems swaying in an autumn breeze ... serious battles between natural enemies that took place in ... to attack by several species of insects that lay ... that can reduce or even completely prevent goldenrod from ...
... arsenal against cancer: Nanoparticles that identify, target and kill ... Led by Carl Batt, the Liberty Hyde Bailey Professor ... something like a dumbbell made of gold sandwiched ... antibodies, which target a molecule found only in colorectal ...
Cached Biology News:Intentional variation increases result validity in mouse testing 2Intentional variation increases result validity in mouse testing 3What should goldenrod do to avoid an insect attack? Duck 2What should goldenrod do to avoid an insect attack? Duck 3Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Zeba Desalt Spin Columns contain a ... that offers exceptional desalting and protein-recovery characteristics ... containing as low as 25 g/ml of ... recovery and > 95% retention of salts ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Synthetic peptide corresponding to ... Antigen Family: Regulator ... Subfamily: not assigned-Regulator ... Storage: Long term: ...
Biology Products: